ReviewBiomedicines2014
Oncolytic Adenoviruses in Cancer Treatment.
Review in Biomedicines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics.Molecular therapy. Oncology · 2026Review
- Adenoviral Vectors in Gene Therapy: A Detailed Overview.Iranian biomedical journal · 2026Review
- Drosophila C Virus and La Jolla Virus Formulations for Plant Protection Against Spotted-WingInsects · 2025Article
- Article
- An Aptamer-Based gFET-Sensor for Specific Quantification of Gene Therapeutic Human Adenovirus Type 5.Biosensors · 2025Article
- Harnessing Oncolytic Viruses for Targeted Therapy in Triple-Negative Breast Cancer.International journal of medical sciences · 2025Review
- A Snapshot of Selenium-enclosed Nanoparticles for the Management of Cancer.Current pharmaceutical design · 2024Review
- Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors.International journal of molecular sciences · 2023Review
- Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions.Frontiers in immunology · 2023Review
- CXCL12 Retargeting of an Oncolytic Adenovirus Vector to the Chemokine CXCR4 and CXCR7 Receptors in Breast Cancer.Journal of cancer therapy · 2021Article
- Enhanced oncolytic adenoviral production by downregulation of death-domain associated protein and overexpression of precursor terminal protein.Scientific reports · 2021Article
- Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies.Cancers · 2020Review
- Review
- Human Desmoglein-2 and Human CD46 Mediate Human Adenovirus Type 55 Infection, but Human Desmoglein-2 Plays the Major Roles.Journal of virology · 2020Article
- Modeling the Efficacy of Oncolytic Adenoviruses In Vitro and In Vivo: Current and Future Perspectives.Cancers · 2020Review
- Article
- Systemic delivery and SPECT/CT in vivo imaging ofScientific reports · 2019Article
- Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma.Oncolytic virotherapy · 2019Review
- Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma.Therapeutic advances in gastroenterology · 2019Review
- NF-κB Signaling in Targeting Tumor Cells by Oncolytic Viruses-Therapeutic Perspectives.Cancers · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic use of viruses against cancer has been revived during the last two decades. Oncolytic viruses replicate and spread inside tumors, amplifying their cytotoxicity and simultaneously reversing the tumor immune suppression. Among different viruses, recombinant adenoviruses designed to replicate selectively in tumor cells have been clinically tested by intratumoral or systemic administration. Limited efficacy has been associated to poor tumor targeting, intratumoral spread, and virocentric immune responses. A deeper understanding of these three barriers will be required to design more effective oncolytic adenoviruses that, alone or combined with chemotherapy or immunotherapy, may become tools for oncologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.